Avastin plus interferon almost doubled patients' time without disease progression, study found
FRIDAY, Dec 21 (HealthDay News) -- A combination treatment with two drugs, Avastin (bevacizumab) plus interferon, extends the life of patients with kidney cancer, European researchers report.
"Based on the result of earlier trials, there is already considerable enthusiasm to use bevacizumab as a new drug for treating kidney cancer patients," noted Dr. Mayer Fishman, an assistant professor in the department of interdisciplinary oncology at the Moffitt Cancer Center of the University of South Florida in Tampa. He was not involved in the study.
Publication of large trials such as this can be expected to support the more widespread use of new drugs such as bevacizumab for kidney cancer therapy, Fishman said.
The study was funded by F. Hoffmann-La Roche Ltd., the maker of Avastin. It is published in the Dec. 22/29 issue of The Lancet.
In a phase III trial, Dr. Bernard Escudier from the Institute Gustave Roussy in Villejuif, France, and colleagues randomly assigned 649 patients with kidney cancer to receive Avastin and interferon or interferon plus a placebo.
Among those receiving combined therapy, 114 died compared with 137 of those receiving interferon alone. Moreover, patients taking Avastin plus interferon survived without any signs of disease progression for an average of 10.2 months. That's almost double the 5.4-month average progression-free survival for those on interferon alone.
"This treatment [bevacizumab plus interferon] is clearly comparable with the most active treatment, and with a very good safety profile, will provide new options for renal cancer patients," Escudier's group concluded.
As more and more targeted drugs are developed, and as more combinations are possible, and as immune treatments become more sophisticated, "optimism is building that we will see more a
All rights reserved